Description
Samsung Biologics’ S-DUAL® platform uses a differentiated asymmetric antibody architecture and an S-KiH (knob-into-hole) Fc engineering strategy to promote selective heterodimer formation and reduce chain mispairing. By promoting correct chain assembly upstream, the platform simplifies downstream purification, increases product purity, and enhances manufacturing robustness.
Features and Benefits:
A key feature of the S-DUAL® approach is that it preserves native antigen-binding regions without requiring engineering of the complementarity-determining regions (CDRs). This retains parental antibody binding while enabling modular adaptation across target combinations. The platform supports scalability from early discovery through manufacturing, enabling drug developers to assess therapeutic performance and developability in a unified workflow.
As the industry expands beyond conventional monoclonal antibodies toward multispecific formats, success will depend on therapeutic efficacy and manufacturability. The S-DUAL® platform addresses both needs by integrating developability considerations directly into the molecular design.